Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
Vaccines
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
For a long time, scientists have been looking into vaccines against pathogenic bacteria in the bowel, particularly those that drugs have proved ineffective against due to resistance.
This finding clarifies how microenvironments and cellular contacts influence the location-specific adaptation of tissue-resident memory CD8 T cells
Researchers used a cross-vaccination strategy in the trial, which involved 33 healthy adult volunteers between the ages of 21 and 45.
C. difficile vaccine protected against C. difficile first-time infections and relapsing infections in animal models by eliciting a strong immune response, facilitating the removal of pre-existing C. diff bacteria from the gut
Despite being influenced by prior vaccinations, the new vaccine produces widely neutralizing antibodies in response.
Pfizer, Team, Public domain, via Wikimedia Commons FDA approves Pfizer’s new pneumococcal vaccines for children and infants on 27th April. The vaccine called Prevenar 20 was made for using against 20 different rate of bacteria. The adult version of the vaccine Prevenar 13 was approved for adults earlier. It is […]
